Drugs / Gruticibart
Gruticibart
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07498517 | Feb 2026 → Feb 2029 expected | thrombotic disease | OHSU Knight Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03612856 | Oct 2018 → Jul 2019 | end stage renal failure, thrombotic disease | Aronora, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gruticibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07498517 ↗ |
| Known as | AB023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03612856 ↗ |
| Known as | Xisomab 3G3 | “Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis” NCT03612856 ↗ |
| Action | Inhibit | “binds factor XI (FXI) and blocks its activation by activated FXII” PMID 34086880 ↗ Dec 2021 |
| Modality | Protein / enzyme biologic | “a unique antibody that binds factor XI (FXI)” PMID 34086880 ↗ Dec 2021 |
| Route | Intravenous | “Given IV or via catheter” NCT07498517 ↗ |